| EMR |
Report |
Adjusted EPS (FQ3'26) |
BEAT |
pred ~$1.72 vs. cons ~$1.68 |
MEDIUM |
| EMR |
Report |
Underlying (organic) sales growth |
IN-LINE |
pred ~5.0% vs. cons ~5.0% |
MEDIUM |
| EMR |
Report |
Adj. segment EBITDA margin |
IN-LINE |
pred ~28.2% vs. cons ~28.0% |
MEDIUM |
| EMR |
Guide |
FY2026 Adjusted EPS guide |
BETTER |
guide ~$6.55-6.60 (raise) vs. cons ~$6.55 (FY2026) |
MEDIUM |
| EMR |
Guide |
Underlying orders growth / book-to-bill |
BETTER |
pred orders ~+5% (B:B ~1.05) vs. cons ~+4% (FQ3'26 trailing) |
MEDIUM |
| EMR |
Guide |
FY2026 underlying sales growth |
UNCHANGED |
guide ~3.0-3.5% vs. cons ~3.0% (FY2026) |
LOW |
| EMR |
Guide |
FY2026 free cash flow |
UNCHANGED |
guide ~$3.5-3.6B vs. cons ~$3.55B (FY2026) |
LOW |
| EMR |
Guide |
Middle East recovery / rebuild opportunity |
UNKNOWN |
pred ~$100M disruption tracking in-line vs. cons ~$100M (FY2026 bal.) |
LOW |
| EMR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| EMR |
Return |
5-day cumulative residual |
-3.0% (FADE) |
Stock ran ~+13% in two weeks into the print, so a modest beat-and-raise is largely priced — classic sell-the-news setup. Out-period math works against follow-through: the FY EPS raise is small and the H2 ramp is back-end/Q4-loaded and lower-quality (project-mix margin pressure, China/Europe soft), so forward organic estimates get trimmed even after an EPS beat. Overbought positioning unwinds over the week; only a large upside orders/ACV surprise would flip it. |
LOW |